Associated Papers
Concurrent Coprimary KIT Exon 17 and BRAF Mutations in a Small Intestinal GI Stromal Tumor-A Case Report.
Ishfaq H et al.
Journal of Gastrointestinal Cancer, 2025
ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors.
Zhang KY et al.
Acta Neuropathologica, 2024
39141113 (PubMed )
Supplement: 401_2024_2785_MOESM2_ESM.xlsx › STab2
Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K).
Spitaleri G et al.
Oncotargets and Therapy, 2015
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Kang HJ et al.
Acta Oncologica (stockholm, Sweden), 2012
Select a paper to view details